BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaplan GG, Bernstein CN, Coward S, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Benchimol EI. The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology. J Can Assoc Gastroenterol 2019;2:S6-S16. [PMID: 31294381 DOI: 10.1093/jcag/gwy054] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Ha R, Keynan Y, Rueda ZV. Increased susceptibility to pneumonia due to tumour necrosis factor inhibition and prospective immune system rescue via immunotherapy. Front Cell Infect Microbiol 2022;12:980868. [DOI: 10.3389/fcimb.2022.980868] [Reference Citation Analysis]
2 Cassol OS, Zabot GP, Saad-Hossne R, Padoin A. Epidemiology of inflammatory bowel diseases in the state of Rio Grande do Sul, Brazil. World J Gastroenterol 2022; 28(30): 4174-4181 [DOI: 10.3748/wjg.v28.i30.4174] [Reference Citation Analysis]
3 Tulewicz-Marti EM, Lewandowski K, Rydzewska G. Bone Metabolism Alteration in Patients with Inflammatory Bowel Disease. J Clin Med 2022;11:4138. [PMID: 35887903 DOI: 10.3390/jcm11144138] [Reference Citation Analysis]
4 Ma X, Di Q, Li X, Zhao X, Zhang R, Xiao Y, Li X, Wu H, Tang H, Quan J, Wu Z, Xiao W, Chen W. Munronoid I Ameliorates DSS-Induced Mouse Colitis by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis Via Modulation of NLRP3. Front Immunol 2022;13:853194. [DOI: 10.3389/fimmu.2022.853194] [Reference Citation Analysis]
5 Fantodji C, Jantchou P, Parent ME, Rousseau MC. Appendectomy and risk for inflammatory bowel disease: effect of age and time post appendectomy - a cohort study. BMJ Open Gastroenterol 2022;9:e000925. [PMID: 35902208 DOI: 10.1136/bmjgast-2022-000925] [Reference Citation Analysis]
6 He YM, Mao R, Yuan G, Liang RM, Long JY, Ye XQ, Iacucci M, Ghosh S, Ben-Horin S, Kaplan GG, He Y, Sung JJY, Peng S, Wang HB, Chen MH. The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018. Therap Adv Gastroenterol 2022;15:17562848221102307. [PMID: 35721841 DOI: 10.1177/17562848221102307] [Reference Citation Analysis]
7 Mo X, Tang K, Deng L, Zhou X, Li X, Zhang Y, Wang J. Prevention of ulcerative colitis by Huangqin decoction: reducing the intestinal epithelial cell apoptosis rate through the IFN-γ/JAK/ETS signalling pathway. Pharm Biol 2022;60:1116-25. [PMID: 35654745 DOI: 10.1080/13880209.2022.2070220] [Reference Citation Analysis]
8 Li K, Feng C, Chen H, Feng Y, Li J. Trends in Worldwide Research in Inflammatory Bowel Disease Over the Period 2012–2021: A Bibliometric Study. Front Med 2022;9:880553. [DOI: 10.3389/fmed.2022.880553] [Reference Citation Analysis]
9 Fenu E, Lukyanov V, Acs A, Radu X, Stypa S, Fischer A, Marshall JK, Oppe M. Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada. PharmacoEconomics Open. [DOI: 10.1007/s41669-022-00331-9] [Reference Citation Analysis]
10 Rines J, Daley K, Loo S, Safari K, Walsh D, Gill M, Moayyedi P, Fernandes A, Marlett N, Marshall D. A patient-led, peer-to-peer qualitative study on the psychosocial relationship between young adults with inflammatory bowel disease and food. Health Expect 2022. [PMID: 35383400 DOI: 10.1111/hex.13488] [Reference Citation Analysis]
11 Dhillon I, Ham J, Maul X, Rosenfeld G, Thamboo A. A pilot prospective prevalence study of chronic rhinosinusitis associated with inflammatory bowel disease. World j otorhinolaryngol -head neck surg . [DOI: 10.1002/wjo2.17] [Reference Citation Analysis]
12 Szilagyi A. Relationships between Western Non Communicable Diseases and Geographic Pattern Modifiers Based on Latitude and Lactase Distributions. Medical Hypotheses 2022. [DOI: 10.1016/j.mehy.2022.110797] [Reference Citation Analysis]
13 Fucilini LMP, Genaro LM, Sousa DCE, Coy CSR, Leal RF, Ayrizono MLS. EPIDEMIOLOGICAL PROFILE AND CLINICAL CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASES IN A BRAZILIAN REFERRAL CENTER. Arq Gastroenterol 2021;58:483-90. [PMID: 34909854 DOI: 10.1590/S0004-2803.202100000-87] [Reference Citation Analysis]
14 Forss A, Clements M, Bergman D, Roelstraete B, Kaplan GG, Myrelid P, Halfvarson J, Olén O, Ludvigsson JF. A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014. Aliment Pharmacol Ther 2021. [PMID: 34907544 DOI: 10.1111/apt.16735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Tandon P, Diong C, Chong RY, Nguyen GC. Regional Variation in Pregnancy Outcomes amongst Women in Inflammatory Bowel Disease: A Population-Based Cohort Study. Can J Gastroenterol Hepatol 2021;2021:3037128. [PMID: 34881209 DOI: 10.1155/2021/3037128] [Reference Citation Analysis]
16 Pratt M, Forbes JD, Knox NC, Bernstein CN, Van Domselaar G. Microbiome-Mediated Immune Signaling in Inflammatory Bowel Disease and Colorectal Cancer: Support From Meta-omics Data. Front Cell Dev Biol 2021;9:716604. [PMID: 34869308 DOI: 10.3389/fcell.2021.716604] [Reference Citation Analysis]
17 Anne Shafer L, Shaffer S, Witt J, Nugent Z, Bernstein CN. IBD Disability Index Is Associated With Both Direct and Indirect Costs of Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab248. [PMID: 34636400 DOI: 10.1093/ibd/izab248] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Chaâr D. Utilisation et incidence des agents biologiques à base d’anticorps monoclonaux durant la grossesse. CMAJ 2021;193:E1537-44. [PMID: 34607850 DOI: 10.1503/cmaj.202391-f] [Reference Citation Analysis]
19 Zou J, Liu C, Jiang S, Qian D, Duan J. Cross Talk between Gut Microbiota and Intestinal Mucosal Immunity in the Development of Ulcerative Colitis. Infect Immun 2021;89:e0001421. [PMID: 33526559 DOI: 10.1128/IAI.00014-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Chaâr D. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 2021;193:E1129-36. [PMID: 34312166 DOI: 10.1503/cmaj.202391] [Reference Citation Analysis]
21 Chen F, Liu Q, Xiong Y, Xu L. Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease. Int J Nanomedicine 2021;16:4225-37. [PMID: 34188471 DOI: 10.2147/IJN.S310952] [Reference Citation Analysis]
22 Kellermayer R, Zilbauer M. The Gut Microbiome and the Triple Environmental Hit Concept of Inflammatory Bowel Disease Pathogenesis. J Pediatr Gastroenterol Nutr 2020;71:589-95. [PMID: 33093364 DOI: 10.1097/MPG.0000000000002908] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
23 Liang L, Lin R, Xie Y, Lin H, Shao F, Rui W, Chen H. The Role of Cyclophilins in Inflammatory Bowel Disease and Colorectal Cancer. Int J Biol Sci 2021;17:2548-60. [PMID: 34326693 DOI: 10.7150/ijbs.58671] [Reference Citation Analysis]
24 Peña-Sánchez JN, Osei JA, Marques Santos JD, Jennings D, Andkhoie M, Brass C, Bukassa-Kazadi G, Lu X, Johnson-Jennings M, Porter L, Porter R, Quintin CL, Sanderson R, Teucher U, Fowler S. Increasing Prevalence and Stable Incidence Rates of Inflammatory Bowel Disease Among First Nations: Population-Based Evidence From a Western Canadian Province. Inflamm Bowel Dis 2021:izab096. [PMID: 34037223 DOI: 10.1093/ibd/izab096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 MacDonald TM, Fisk JD, Bernstein CN, El-Gabalawy R, Hitchon CA, Kornelsen J, Patten SB, Tisseverasinghe A, Marrie RA. The association between childhood maltreatment and pain catastrophizing in individuals with immune-mediated inflammatory diseases. J Psychosom Res 2021;145:110479. [PMID: 33814193 DOI: 10.1016/j.jpsychores.2021.110479] [Reference Citation Analysis]
26 Loftus EV. The increasing burden of inflammatory bowel disease. Med J Aust 2021;214:361-2. [PMID: 33774833 DOI: 10.5694/mja2.51001] [Reference Citation Analysis]
27 Osei JA, Peña-sánchez JN, Fowler SA, Muhajarine N, Kaplan GG, Lix LM. Increasing Prevalence and Direct Health Care Cost of Inflammatory Bowel Disease Among Adults: A Population-Based Study From a Western Canadian Province. Journal of the Canadian Association of Gastroenterology 2021. [DOI: 10.1093/jcag/gwab003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Bruinooge A, Liu Q, Tian Y, Jiang W, Li Y, Xu W, Bernstein CN, Hu P. Genetic predictors of gene expression associated with psychiatric comorbidity in patients with inflammatory bowel disease - A pilot study. Genomics 2021;113:919-32. [PMID: 33588072 DOI: 10.1016/j.ygeno.2021.02.001] [Reference Citation Analysis]
29 Yao Q, Li H, Fan L, Zhang Y, Zhao S, Zheng N, Wang J. Dietary Regulation of the Crosstalk between Gut Microbiome and Immune Response in Inflammatory Bowel Disease. Foods 2021;10:368. [PMID: 33567698 DOI: 10.3390/foods10020368] [Reference Citation Analysis]
30 Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. Front Cell Dev Biol 2021;9:612830. [PMID: 33614645 DOI: 10.3389/fcell.2021.612830] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Bernstein CN, Kuenzig ME, Coward S, Nugent Z, Nasr A, El-Matary W, Singh H, Kaplan GG, Benchimol EI. Increased Incidence of Inflammatory Bowel Disease After Hirschsprung Disease: A Population-based Cohort Study. J Pediatr 2021;233:98-104.e2. [PMID: 33545193 DOI: 10.1016/j.jpeds.2021.01.060] [Reference Citation Analysis]
32 Zhang H, Zhang F, Li W. Function of intestinal barrier protected by regulating the miR-199a-3p in ulcerative colitis: Modulation of IL-23/IL-17A axis. Fundam Clin Pharmacol 2021;35:852-60. [PMID: 33475196 DOI: 10.1111/fcp.12650] [Reference Citation Analysis]
33 Szilagyi A, Smith BE, Sebbag N, Xue X. Global associations of national economic wealth are more robust with inflammatory bowel diseases than with obesity. Med Hypotheses 2021;148:110505. [PMID: 33515916 DOI: 10.1016/j.mehy.2021.110505] [Reference Citation Analysis]
34 Jacob EM, Borah A, Pillai SC, Kumar DS. Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. Nanomaterials (Basel) 2020;10:E2460. [PMID: 33316984 DOI: 10.3390/nano10122460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
35 Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:56-66. [PMID: 33033392 DOI: 10.1038/s41575-020-00360-x] [Cited by in Crossref: 123] [Cited by in F6Publishing: 104] [Article Influence: 61.5] [Reference Citation Analysis]
36 Willows S, Alam SB, Sandhu JK, Kulka M. A Canadian perspective on severe acute respiratory syndrome coronavirus 2 infection and treatment: how prevalent underlying inflammatory disease contributes to pathogenesis. Biochem Cell Biol 2021;99:173-94. [PMID: 33027600 DOI: 10.1139/bcb-2020-0341] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 26.0] [Reference Citation Analysis]
38 Goldberg IP, Chang SL, Kundu SD, Chung BI, Singer EA. Impact of inflammatory bowel disease on radical prostatectomy outcomes and costs of care. Prostate Int 2021;9:66-71. [PMID: 34386447 DOI: 10.1016/j.prnil.2020.08.001] [Reference Citation Analysis]
39 Osei JA, Peña-Sánchez JN, Fowler SA, Muhajarine N, Kaplan GG, Lix LM. Population-Based Evidence From a Western Canadian Province of the Decreasing Incidence Rates and Trends of Inflammatory Bowel Disease Among Adults. J Can Assoc Gastroenterol 2021;4:186-93. [PMID: 34337319 DOI: 10.1093/jcag/gwaa028] [Reference Citation Analysis]
40 Pasvol TJ, Horsfall L, Bloom S, Segal AW, Sabin C, Field N, Rait G. Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study. BMJ Open 2020;10:e036584. [PMID: 32690524 DOI: 10.1136/bmjopen-2019-036584] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
41 Kaplan GG, Ma C, Seow CH, Kroeker KI, Panaccione R. The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. J Can Assoc Gastroenterol 2020;3:234-42. [PMID: 32905124 DOI: 10.1093/jcag/gwz044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
42 Singh S, Picardo S, Seow CH. Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric. Clin Gastroenterol Hepatol 2020;18:1367-80. [PMID: 31712084 DOI: 10.1016/j.cgh.2019.11.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
43 Windsor JW, Kaplan GG. Evolving Epidemiology of IBD. Curr Gastroenterol Rep. 2019;21:40. [PMID: 31338613 DOI: 10.1007/s11894-019-0705-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 16.3] [Reference Citation Analysis]